QQQ   419.50 (-0.92%)
AAPL   165.60 (-0.86%)
MSFT   402.53 (-0.43%)
META   489.57 (-2.44%)
GOOGL   155.31 (-0.45%)
AMZN   176.52 (-1.51%)
TSLA   149.91 (-0.01%)
NVDA   825.35 (-2.52%)
AMD   150.64 (-2.86%)
NIO   3.87 (-3.25%)
BABA   68.81 (-0.10%)
T   16.31 (-0.12%)
F   12.13 (+0.58%)
MU   108.96 (-2.65%)
GE   150.68 (-1.48%)
CGC   7.75 (-1.02%)
DIS   111.76 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.64 (+0.98%)
PYPL   62.01 (-0.14%)
XOM   120.40 (+1.59%)
QQQ   419.50 (-0.92%)
AAPL   165.60 (-0.86%)
MSFT   402.53 (-0.43%)
META   489.57 (-2.44%)
GOOGL   155.31 (-0.45%)
AMZN   176.52 (-1.51%)
TSLA   149.91 (-0.01%)
NVDA   825.35 (-2.52%)
AMD   150.64 (-2.86%)
NIO   3.87 (-3.25%)
BABA   68.81 (-0.10%)
T   16.31 (-0.12%)
F   12.13 (+0.58%)
MU   108.96 (-2.65%)
GE   150.68 (-1.48%)
CGC   7.75 (-1.02%)
DIS   111.76 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.64 (+0.98%)
PYPL   62.01 (-0.14%)
XOM   120.40 (+1.59%)
QQQ   419.50 (-0.92%)
AAPL   165.60 (-0.86%)
MSFT   402.53 (-0.43%)
META   489.57 (-2.44%)
GOOGL   155.31 (-0.45%)
AMZN   176.52 (-1.51%)
TSLA   149.91 (-0.01%)
NVDA   825.35 (-2.52%)
AMD   150.64 (-2.86%)
NIO   3.87 (-3.25%)
BABA   68.81 (-0.10%)
T   16.31 (-0.12%)
F   12.13 (+0.58%)
MU   108.96 (-2.65%)
GE   150.68 (-1.48%)
CGC   7.75 (-1.02%)
DIS   111.76 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.64 (+0.98%)
PYPL   62.01 (-0.14%)
XOM   120.40 (+1.59%)
QQQ   419.50 (-0.92%)
AAPL   165.60 (-0.86%)
MSFT   402.53 (-0.43%)
META   489.57 (-2.44%)
GOOGL   155.31 (-0.45%)
AMZN   176.52 (-1.51%)
TSLA   149.91 (-0.01%)
NVDA   825.35 (-2.52%)
AMD   150.64 (-2.86%)
NIO   3.87 (-3.25%)
BABA   68.81 (-0.10%)
T   16.31 (-0.12%)
F   12.13 (+0.58%)
MU   108.96 (-2.65%)
GE   150.68 (-1.48%)
CGC   7.75 (-1.02%)
DIS   111.76 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.64 (+0.98%)
PYPL   62.01 (-0.14%)
XOM   120.40 (+1.59%)
Free Trial

Travere Therapeutics (TVTX) Stock Forecast & Price Target

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free tvtx Stock Alerts
$5.81
+0.01 (+0.17%)
(As of 11:10 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Travere Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$17.85
207.16% Upside
High Forecast$35.00
Average Forecast$17.85
Low Forecast$9.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$17.85$17.85$17.92$33.09
Predicted Upside207.16% Upside79.55% Upside78.78% Upside60.66% Upside
Get Travere Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

TVTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Travere Therapeutics Stock vs. The Competition

TypeTravere TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside207.69% Upside928.11% Upside12.31% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/17/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$13.00+116.31%
3/27/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Neutral
3/13/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$17.00+133.20%
2/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$8.00 ➝ $9.00+8.43%
1/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$10.00 ➝ $11.00+23.18%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetHold ➝ Hold$8.00 ➝ $10.00+17.10%
12/5/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$7.00 ➝ $10.00+58.98%
9/22/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$30.00 ➝ $14.00+89.19%
9/22/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$41.00 ➝ $27.00+253.40%
9/22/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$31.00 ➝ $12.00+57.07%
9/21/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$26.00+66.35%
7/18/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$37.00 ➝ $35.00+120.54%
5/22/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$30.00+82.37%
5/5/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeSell ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:26 AM ET.

TVTX Price Target - Frequently Asked Questions

What is Travere Therapeutics's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Travere Therapeutics stock is Moderate Buy based on the current 6 hold ratings and 9 buy ratings for TVTX. The average twelve-month price prediction for Travere Therapeutics is $17.85 with a high price target of $35.00 and a low price target of $9.00. Learn more on TVTX's analyst rating history.

Do Wall Street analysts like Travere Therapeutics more than its competitors?

Analysts like Travere Therapeutics less than other Medical companies. The consensus rating score for Travere Therapeutics is 2.60 while the average consensus rating score for medical companies is 2.68. Learn more on how TVTX compares to other companies.

Does Travere Therapeutics's stock price have much upside?

According to analysts, Travere Therapeutics's stock has a predicted upside of 81.87% based on their 12-month stock forecasts.

What analysts cover Travere Therapeutics?

Travere Therapeutics has been rated by Guggenheim, HC Wainwright, Wedbush, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:TVTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
My biggest AI fear
Paradigm Press
How Biden has already won 2024
Porter & Company